Kreitzer Anatol sold $96K of MPLT
Kreitzer Anatol (Chief Discovery Officer) sold 12,248 shares of MapLight Therapeutics, Inc. (MPLT) at $7.84 on 2026-10-15.
How this was made
The 30-second read
Why it matters
The only actionable new fact is the insider’s open-market sale details; there is no accompanying corporate event, clinical update, or guidance change.
Market read
Traders may monitor for follow-on insider activity, but this filing alone is unlikely to drive a major repricing without additional fundamental catalysts.
What to watch
The article does not provide context on total insider holdings, prior sale patterns, tax events, or whether other insiders sold/bought around the same period.
Background
The article is an SEC EDGAR Form 4 insider transaction disclosure for MapLight Therapeutics, Inc.
Ticker impact
MapLight Therapeutics disclosed a Form 4 showing CDO Kreitzer Anatol sold 12,248 shares at $7.84 on 2026-10-15.
Likely limited near-term impact, with any effect driven by sentiment rather than new company-specific information.
This is a routine SEC Form 4 insider sale with no 10b5-1 plan and no accompanying operational or financial update in the text.
Market effects
Minimal, as the disclosure is company-specific and does not indicate sector-wide regulatory or clinical changes.
None indicated.
None indicated.
Counterpoint
The sale may be planned for personal liquidity or diversification, and the absence of a 10b5-1 plan in the text does not necessarily imply negative expectations.
Key entities
- issuerMapLight Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderKreitzer Anatol
Chief Discovery Officer who sold shares.